Record Information |
---|
Version | 5.0 |
---|
Status | Detected but not Quantified |
---|
Creation Date | 2012-09-06 15:16:50 UTC |
---|
Update Date | 2022-03-07 02:51:42 UTC |
---|
HMDB ID | HMDB0014704 |
---|
Secondary Accession Numbers | |
---|
Metabolite Identification |
---|
Common Name | Carbamazepine |
---|
Description | Carbamazepine, also known as tegretol or carnexiv, belongs to the class of organic compounds known as dibenzazepines. Dibenzazepines are compounds with two benzene rings connected by an azepine ring. Azepine is an unsaturated seven-member heterocycle with one nitrogen atom replacing a carbon atom. Carbamazepine is an extremely weak basic (essentially neutral) compound (based on its pKa). Within humans, carbamazepine participates in a number of enzymatic reactions. In particular, carbamazepine can be converted into 3-hydroxycarbamazepine through its interaction with the enzymes cytochrome P450 3A4, cytochrome P450 2B6, and cytochrome P450 3A7. In addition, carbamazepine can be converted into carbamazepine-10,11-epoxide; which is catalyzed by the enzymes cytochrome P450 2C8, cytochrome P450 3A4, cytochrome P450 3A5, cytochrome P450 3A7, and cytochrome P450 2C19. In humans, carbamazepine is involved in carbamazepine metabolism pathway. Carbamazepine is a potentially toxic compound. A dibenzoazepine that is 5H-dibenzoazepine carrying a carbamoyl substituent at the azepine nitrogen, used as an anticonvulsant. |
---|
Structure | NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12 InChI=1S/C15H12N2O/c16-15(18)17-13-7-3-1-5-11(13)9-10-12-6-2-4-8-14(12)17/h1-10H,(H2,16,18) |
---|
Synonyms | Value | Source |
---|
5-Carbamoyl-5H-dibenz(b,F)azepine | ChEBI | 5-Carbamoyl-5H-dibenz[b,F]azepine | ChEBI | 5-Carbamoyl-5H-dibenzo(b,F)azepine | ChEBI | 5-Carbamyl-5H-dibenzo(b,F)azepine | ChEBI | 5H-Dibenz(b,F)azepine-5-carboxamide | ChEBI | Carbamazepen | ChEBI | Carbamazepina | ChEBI | Carbamazepinum | ChEBI | Carnexiv | ChEBI | Equetro | Kegg | Tegretol | Kegg | Carbamezepine | HMDB | Neurotol | HMDB | Amizepine | HMDB | Carbamazepine acetate | HMDB | Carbamazepine anhydrous | HMDB | Carbamazepine dihydrate | HMDB | Carbamazepine hydrochloride | HMDB | Carbamazepine phosphate | HMDB | Epitol | HMDB | Finlepsin | HMDB | Carbamazepine L-tartrate (4:1) | HMDB | Carbamazepine sulfate (2:1) | HMDB | Carbazepin | HMDB |
| Show more...
---|
Chemical Formula | C15H12N2O |
---|
Average Molecular Weight | 236.2686 |
---|
Monoisotopic Molecular Weight | 236.094963016 |
---|
IUPAC Name | 2-azatricyclo[9.4.0.0^{3,8}]pentadeca-1(15),3,5,7,9,11,13-heptaene-2-carboxamide |
---|
Traditional Name | 2-azatricyclo[9.4.0.0^{3,8}]pentadeca-1(15),3,5,7,9,11,13-heptaene-2-carboxamide |
---|
CAS Registry Number | 298-46-4 |
---|
SMILES | NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12 |
---|
InChI Identifier | InChI=1S/C15H12N2O/c16-15(18)17-13-7-3-1-5-11(13)9-10-12-6-2-4-8-14(12)17/h1-10H,(H2,16,18) |
---|
InChI Key | FFGPTBGBLSHEPO-UHFFFAOYSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as dibenzazepines. Dibenzazepines are compounds with two benzene rings connected by an azepine ring. Azepine is an unsaturated seven-member heterocycle with one nitrogen atom replacing a carbon atom. |
---|
Kingdom | Organic compounds |
---|
Super Class | Organoheterocyclic compounds |
---|
Class | Benzazepines |
---|
Sub Class | Dibenzazepines |
---|
Direct Parent | Dibenzazepines |
---|
Alternative Parents | |
---|
Substituents | - Dibenzazepine
- Azepine
- Benzenoid
- Urea
- Carbonic acid derivative
- Azacycle
- Organic nitrogen compound
- Organic oxygen compound
- Organopnictogen compound
- Organic oxide
- Hydrocarbon derivative
- Organooxygen compound
- Organonitrogen compound
- Carbonyl group
- Aromatic heteropolycyclic compound
|
---|
Molecular Framework | Aromatic heteropolycyclic compounds |
---|
External Descriptors | |
---|
Ontology |
---|
Physiological effect | Not Available |
---|
Disposition | |
---|
Process | |
---|
Role | |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | 190.2 °C | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | 0.15 g/L | Not Available | LogP | 2.3 | Not Available |
|
---|
Experimental Chromatographic Properties | Experimental Collision Cross Sections |
---|
Predicted Molecular Properties | | Show more...
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatizedDerivatizedDerivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
---|
Carbamazepine,1TMS,isomer #1 | C[Si](C)(C)NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C21 | 2243.7 | Semi standard non polar | 33892256 | Carbamazepine,1TMS,isomer #1 | C[Si](C)(C)NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C21 | 2248.4 | Standard non polar | 33892256 | Carbamazepine,1TMS,isomer #1 | C[Si](C)(C)NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C21 | 3415.9 | Standard polar | 33892256 | Carbamazepine,2TMS,isomer #1 | C[Si](C)(C)N(C(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C21)[Si](C)(C)C | 2331.5 | Semi standard non polar | 33892256 | Carbamazepine,2TMS,isomer #1 | C[Si](C)(C)N(C(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C21)[Si](C)(C)C | 2520.5 | Standard non polar | 33892256 | Carbamazepine,2TMS,isomer #1 | C[Si](C)(C)N(C(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C21)[Si](C)(C)C | 3350.4 | Standard polar | 33892256 | Carbamazepine,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C21 | 2447.9 | Semi standard non polar | 33892256 | Carbamazepine,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C21 | 2444.3 | Standard non polar | 33892256 | Carbamazepine,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C21 | 3511.7 | Standard polar | 33892256 | Carbamazepine,2TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)N(C(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C21)[Si](C)(C)C(C)(C)C | 2714.8 | Semi standard non polar | 33892256 | Carbamazepine,2TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)N(C(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C21)[Si](C)(C)C(C)(C)C | 2849.9 | Standard non polar | 33892256 | Carbamazepine,2TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)N(C(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C21)[Si](C)(C)C(C)(C)C | 3411.7 | Standard polar | 33892256 |
| Show more...
---|
Spectra |
---|
| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted GC-MS | Predicted GC-MS Spectrum - Carbamazepine GC-MS (Non-derivatized) - 70eV, Positive | splash10-0006-3970000000-8f03b4d1ea6cec6641ec | 2017-09-01 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Carbamazepine GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | MS | Mass Spectrum (Electron Ionization) | splash10-0006-1910000000-4b2dc85e8da73b101ed2 | 2014-09-20 | Not Available | View Spectrum |
MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Experimental LC-MS/MS | LC-MS/MS Spectrum - Carbamazepine LC-ESI-qTof , Positive-QTOF | splash10-000f-1940000000-9677ddf985ba43e76817 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Carbamazepine LC-ESI-qTof , Positive-QTOF | splash10-000f-0930000000-b2a70bea75cef0c24556 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Carbamazepine LC-ESI-qTof , Positive-QTOF | splash10-0006-2900000000-86f35079f274f4014c3d | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Carbamazepine LC-ESI-QTOF , positive-QTOF | splash10-000i-0090000000-be63f70e101a786a369b | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Carbamazepine LC-ESI-QTOF , positive-QTOF | splash10-0006-0910000000-f171a56d3bbeaef24ff4 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Carbamazepine LC-ESI-QTOF , positive-QTOF | splash10-0006-0900000000-a82def037961e9b94a9a | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Carbamazepine LC-ESI-QTOF , positive-QTOF | splash10-0006-0900000000-484ce005b4ae5d01fc2a | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Carbamazepine LC-ESI-QTOF , positive-QTOF | splash10-0006-0900000000-a6992953eac16c120e74 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Carbamazepine LC-ESI-ITFT , positive-QTOF | splash10-0006-0900000000-7a1010be5231131649eb | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Carbamazepine LC-ESI-ITFT , positive-QTOF | splash10-000i-0090000000-51ef94c86cca9b541780 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Carbamazepine LC-ESI-ITFT , positive-QTOF | splash10-000i-0490000000-4484ac1671912bc60ba9 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Carbamazepine LC-ESI-ITFT , positive-QTOF | splash10-0006-0910000000-e5ca06888593ada95f15 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Carbamazepine LC-ESI-ITFT , positive-QTOF | splash10-0006-0900000000-5742023f1e263fb40066 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Carbamazepine LC-ESI-ITFT , positive-QTOF | splash10-0006-0900000000-f27fb9d17b228cc328b8 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Carbamazepine LC-ESI-ITFT , positive-QTOF | splash10-0006-0900000000-63c554c485fd1d117082 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Carbamazepine LC-ESI-ITFT , positive-QTOF | splash10-000i-0090000000-c6c89d3e663885fcc080 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Carbamazepine LC-ESI-ITFT , positive-QTOF | splash10-000i-0490000000-8a1d8d7b932f1b0ad45e | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Carbamazepine LC-ESI-ITFT , positive-QTOF | splash10-0006-0910000000-843efaf5294cb110e0b9 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Carbamazepine LC-ESI-ITFT , positive-QTOF | splash10-0006-0900000000-7eb2855f73a1ed729181 | 2017-09-14 | HMDB team, MONA | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Carbamazepine 10V, Positive-QTOF | splash10-000i-0290000000-926be8d54e58a26d40d3 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Carbamazepine 20V, Positive-QTOF | splash10-000f-0950000000-68b3fa7ce7380dc8311e | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Carbamazepine 40V, Positive-QTOF | splash10-0006-1900000000-60a9fc188e8c79505dee | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Carbamazepine 10V, Negative-QTOF | splash10-0006-8960000000-8aa13e4d27b1afb8662d | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Carbamazepine 20V, Negative-QTOF | splash10-0006-2900000000-6d502f01257a774384bf | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Carbamazepine 40V, Negative-QTOF | splash10-0006-9500000000-3d22d3677d67ba94c4ac | 2016-08-03 | Wishart Lab | View Spectrum |
NMR SpectraSpectrum Type | Description | Deposition Date | Source | View |
---|
| Show more...
---|
Biological Properties |
---|
Cellular Locations | |
---|
Biospecimen Locations | |
---|
Tissue Locations | Not Available |
---|
Pathways | |
---|
Normal Concentrations |
---|
| |
Blood | Expected but not Quantified | Not Quantified | Not Available | Not Available | Taking drug identified by DrugBank entry DB00564 | | details | Blood | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Normal | | details | Urine | Expected but not Quantified | Not Quantified | Not Available | Not Available | Taking drug identified by DrugBank entry DB00564 | | details | Urine | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Normal | | details |
|
---|
Abnormal Concentrations |
---|
| Not Available |
---|
Predicted Concentrations |
---|
| |
Blood | 0.000 uM | Adult (>18 years old) | Both | Normal | Predicted based on drug qualities | Blood | 0.000 umol/mmol creatinine | Adult (>18 years old) | Both | Normal | Predicted based on drug qualities |
|
---|
Associated Disorders and Diseases |
---|
Disease References | None |
---|
Associated OMIM IDs | None |
---|
External Links |
---|
DrugBank ID | DB00564 |
---|
Phenol Explorer Compound ID | Not Available |
---|
FooDB ID | Not Available |
---|
KNApSAcK ID | Not Available |
---|
Chemspider ID | 2457 |
---|
KEGG Compound ID | C06868 |
---|
BioCyc ID | Not Available |
---|
BiGG ID | Not Available |
---|
Wikipedia Link | Carbamazepine |
---|
METLIN ID | Not Available |
---|
PubChem Compound | 2554 |
---|
PDB ID | Not Available |
---|
ChEBI ID | 3387 |
---|
Food Biomarker Ontology | Not Available |
---|
VMH ID | Not Available |
---|
MarkerDB ID | Not Available |
---|
Good Scents ID | Not Available |
---|
References |
---|
Synthesis Reference | Not Available |
---|
Material Safety Data Sheet (MSDS) | Download (PDF) |
---|
General References | - Staines AG, Coughtrie MW, Burchell B: N-glucuronidation of carbamazepine in human tissues is mediated by UGT2B7. J Pharmacol Exp Ther. 2004 Dec;311(3):1131-7. Epub 2004 Aug 3. [PubMed:15292462 ]
- Sisodiya SM, Goldstein DB: Drug resistance in epilepsy: more twists in the tale. Epilepsia. 2007 Dec;48(12):2369-70. [PubMed:18088268 ]
|
---|